S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
New CBOE “special perk” helps traders target income every weekend (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
New CBOE “special perk” helps traders target income every weekend (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
New CBOE “special perk” helps traders target income every weekend (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
New CBOE “special perk” helps traders target income every weekend (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Vyant Bio Stock Price, News & Analysis (OTCMKTS:VYNT)

$0.18
0.00 (0.00%)
(As of 12/7/2023 ET)
Compare
Today's Range
$0.17
$0.19
50-Day Range
$0.15
$0.20
52-Week Range
$0.14
$1.58
Volume
1,816 shs
Average Volume
168,915 shs
Market Capitalization
$1.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VYNT stock logo

About Vyant Bio Stock (OTCMKTS:VYNT)

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.

VYNT Stock Price History

VYNT Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Vyant Bio Provides Update on Winddown Activities
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Vyant Bio Announces Completion of StemoniX Asset Sale
AI Can Find Cancer’s Origin: Study
See More Headlines
Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
12/07/2023
Next Earnings (Estimated)
12/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:VYNT
Employees
4
Year Founded
N/A

Profitability

Net Income
$-22,690,000.00
Net Margins
-3,474.81%
Pretax Margin
-3,281.86%

Debt

Sales & Book Value

Annual Sales
$666,000.00
Book Value
$1.69 per share

Miscellaneous

Free Float
5,724,000
Market Cap
$1.12 million
Optionable
Not Optionable
Beta
1.68
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Andrew D.C. LaFrence CPA (Age 60)
    President, CEO & CFO
    Comp: $407.4k
  • Mr. Yung-Ping Yeh M.B.A. (Age 47)
    M.S., P.M.P., Co-Founder & Director
    Comp: $22.5k














VYNT Stock Analysis - Frequently Asked Questions

Should I buy or sell Vyant Bio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VYNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VYNT, but not buy additional shares or sell existing shares.
View VYNT analyst ratings
or view top-rated stocks.

How have VYNT shares performed in 2023?

Vyant Bio's stock was trading at $0.7025 at the start of the year. Since then, VYNT stock has decreased by 74.7% and is now trading at $0.1775.
View the best growth stocks for 2023 here
.

How were Vyant Bio's earnings last quarter?

Vyant Bio, Inc. (OTCMKTS:VYNT) released its quarterly earnings data on Thursday, November, 11th. The company reported ($0.75) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.75). The company earned $1.51 million during the quarter, compared to the consensus estimate of $2.19 million. Vyant Bio had a negative net margin of 3,474.81% and a negative trailing twelve-month return on equity of 151.82%. During the same period last year, the company earned ($2.90) EPS.

When did Vyant Bio's stock split?

Shares of Vyant Bio reverse split on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Vyant Bio?

Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:VYNT) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -